K
Kazimierz Kuliczkowski
Researcher at Wrocław Medical University
Publications - 248
Citations - 5273
Kazimierz Kuliczkowski is an academic researcher from Wrocław Medical University. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 31, co-authored 244 publications receiving 4653 citations. Previous affiliations of Kazimierz Kuliczkowski include Mayo Clinic & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu,Jizhong Liu,Abdelbasset Hamrouni,Abdelbasset Hamrouni,Darius Wolowiec,Valérie Coiteux,Kazimierz Kuliczkowski,Dominique Hetuin,Dominique Hetuin,Aurore Saudemont,Aurore Saudemont,Bruno Quesnel,Bruno Quesnel +12 more
TL;DR: B7-H1 expression by MM cells represents a possible immune escape mechanism that could be targeted therapeutically through inhibition of MyD88/TRAF6 and MEK/ERK/STAT1.
Journal ArticleDOI
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Animesh Pardanani,Claire N. Harrison,Jorge E. Cortes,Francisco Cervantes,Ruben A. Mesa,Donald Milligan,Tamas Masszi,Elena Mishchenko,Eric Jourdan,Alessandro M. Vannucchi,Mark Drummond,Mindaugas Jurgutis,Kazimierz Kuliczkowski,Emanuil Gheorghita,Francesco Passamonti,Frank Neumann,Abhay Patki,Guozhi Gao,Ayalew Tefferi +18 more
TL;DR: Fedratinib therapy significantly reduced splenomegaly and symptom burden in patients with MF and was accompanied by toxic effects in some patients, the most important being encephalopathy of unknown mechanism.
Journal ArticleDOI
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Philipp le Coutre,Oliver G. Ottmann,Francis J. Giles,Dong-Wook Kim,Jorge E. Cortes,Norbert Gattermann,Jane F. Apperley,Richard A. Larson,Elisabetta Abruzzese,Stephen G. O'Brien,Kazimierz Kuliczkowski,Andreas Hochhaus,François Xavier Mahon,Giuseppe Saglio,Marco De Gobbi,Yok-Lam Kwong,Michele Baccarani,Timothy P. Hughes,Giovanni Martinelli,Jerald P. Radich,Ming Zheng,Yaping Shou,Hagop M. Kantarjian +22 more
TL;DR: In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP.
Journal ArticleDOI
Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
Jerzy Holowiecki,Sebastian Grosicki,Sebastian Giebel,Tadeusz Robak,Slawomira Kyrcz-Krzemien,Kazimierz Kuliczkowski,Aleksander B. Skotnicki,Andrzej Hellmann,Kazimierz Sulek,Anna Dmoszynska,Janusz Kloczko,Wiesław Wiktor Jędrzejczak,Barbara Zdziarska,Krzysztof Warzocha,Krystyna Zawilska,Mieczysław Komarnicki,Marek Kielbinski,Beata Piatkowska-Jakubas,Agnieszka Wierzbowska,Malgorzata Wach,Olga Haus +20 more
TL;DR: The addition of cladribine to the standard induction regimen is associated with increased rate of complete remission and improved survival of adult patients with AML.
Journal ArticleDOI
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
Gustaaf W. van Imhoff,Andrew McMillan,Matthew J. Matasar,John Radford,Kirit M. Ardeshna,Kazimierz Kuliczkowski,Won Seog Kim,Xiaonan Hong,Jette Soenderskov Goerloev,Andrew Davies,María Dolores Caballero Barrigón,Michinori Ogura,Sirpa Leppä,Michael Fennessy,Qiming Liao,Bronno van der Holt,Steen Lisby,Anton Hagenbeek +17 more
TL;DR: No difference in efficacy was found between O- DHAP and R-DHAP as salvage treatment of relapsed or refractory DLBCL, and positron emission tomography negativity before ASCT was highly predictive for superior outcome.